loader2
Login Open ICICI 3-in-1 Account
  • Text Size
  • Text to Speech
  • Color Contrast
  • Pause Animations

Open ICICI
3-in-1 Account

Manage your Savings, Demat and Trading Account conveniently at one place

+91

BLOG

Zydus has partnered with MSN Laboratories to launch generic Riociguat Tablets in the US

ICICIdirect Research 06 Oct 2026 DISCLAIMER

News: Zydus has partnered with MSN Laboratories to launch generic Riociguat Tablets in the US, becoming the first companies to launch a generic version of Bayer’s Adempas (riociguat) in the market. Developed and manufactured by MSN, the drug is indicated for adults with persistent or recurrent chronic thromboembolic pulmonary hypertension (CTEPH) following surgical treatment. Adempas recorded global sales of approximately €745 million (~US$850 million) in 2025, according to Bayer’s Annual Report 2025.

View: Given the decent market size and limited competition, the product could represent a meaningful opportunity for Zydus. Further clarity on the product potential and the marketing arrangement should emerge during the upcoming earnings call.

Impact: Positive

Download
ICICI Direct app

Invest, Track, and Manage your Portfolio Anytime, Anywhere

Download
ICICI Direct app

Invest, Track, and Manage your Portfolio Anytime, Anywhere